FDA declines to approve AbbVie's Botox follow-up
AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
Newsletters and Deep Dive digital magazine
AbbVie's bid to bring a rapid and shorter-acting botulinum toxin product to the US market has been knocked back by the FDA.
Regeneron's Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.
Roche has started its financial reporting for 2026 with a 5% fall in first-quarter revenues, but says its underlying performance remains strong.
Sanofi's new chief executive, Belén Garijo, will see her tenure at the company kick-started by a strong 2026 first quarter.
AbbVie's $100bn programme of facility investments in the US has continued with a new 185-acre campus in Durham, North Carolina.
Editor's Picks
Newsletters and Deep Dive
digital magazine